Rafael Amado Sells 2,957 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 2,957 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $18.63, for a total transaction of $55,088.91. Following the sale, the insider owned 44,757 shares of the company’s stock, valued at $833,822.91. This trade represents a 6.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Rafael Amado also recently made the following trade(s):

• On Wednesday, December 31st, Rafael Amado sold 10,787 shares of Zai Lab stock. The shares were sold at an average price of $17.43, for a total transaction of $188,017.41.

Zai Lab Stock Down 0.2%

Zai Lab stock opened at $19.02 on Wednesday. The firm has a 50 day moving average price of $18.69 and a 200-day moving average price of $22.87. Zai Lab Limited Unsponsored ADR has a twelve month low of $15.96 and a twelve month high of $44.34. The company has a market capitalization of $2.15 billion, a P/E ratio of -11.81 and a beta of 0.85.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.02). Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%.The company had revenue of $127.60 million during the quarter, compared to the consensus estimate of $122.67 million. Equities analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC grew its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,396 shares of the company’s stock after buying an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. 41.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. UBS Group initiated coverage on shares of Zai Lab in a research note on Wednesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Zacks Research lowered shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Cantor Fitzgerald cut their price objective on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Finally, Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a research note on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.17.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.